Daniel Gentry
Surgical · Baltimore, MDNPI 1093231755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations.
Across 66 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$205
- Boston Scientific$203
- Sumitomo Pharma America, Inc.$185
- Urovant Sciences Inc$145
- Olympus America Inc.$135
- 180 Medical, Inc.$87
- plus $722 from 21 others
What the payments were for
- Food & beverage$1,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $205 |
| Boston Scientific | 3 | $203 |
| Sumitomo Pharma America, Inc. | 9 | $185 |
| Urovant Sciences Inc | 7 | $145 |
| Olympus America Inc. | 3 | $135 |
| 180 Medical, Inc. | 4 | $87 |
| Merck | 5 | $86 |
| Astellas Pharma US Inc | 3 | $77 |
| Teleflex LLC | 2 | $63 |
| Tolmar Pharmaceuticals, Inc. | 2 | $44 |
| ABC Home Medical Supply, Inc. | 2 | $42 |
| Laborie Medical Technologies Corp. | 1 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| Baxter Healthcare | 1 | $34 |
| Myovant Sciences Inc. | 1 | $32 |
| Medtronic | 1 | $30 |
| Tolmar, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Angiodynamics, Inc. | 1 | $26 |
| Valencia Technologies Corporation | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $25 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| Convatec Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $17 |
| Photocure Inc | 1 | $16 |
| Profound Medical Corp. | 1 | $15 |
| Sagent Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700$146
How this compares
$1,682 in reported general payments places this provider in the 85th percentile of 277 surgical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 163 | $136,063 |
| MyrbetriqMirabegron | 102 | $77,968 |
| Testosterone | 21 | $12,226 |
| Tamsulosin Hcl | 372 | $8,064 |
| Methenamine Hippurate | 34 | $2,781 |
| Potassium Citrate ErPotassium Citrate | 33 | $2,451 |
| Finasteride | 156 | $2,359 |
| Solifenacin Succinate | 56 | $2,335 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 86 | $2,122 |
| Oxybutynin Chloride ErOxybutynin Chloride | 65 | $1,680 |
| Silodosin | 11 | $1,129 |
| Testosterone Cypionate | 15 | $862 |
| Dutasteride | 11 | $607 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 72 | $554 |
| NitrofurantoinNitrofurantoin Macrocrystal | 19 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $185 | $136,063163 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $77,968102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 277 surgical providers in Maryland.
Other surgical in Baltimore
- Erika NigamBaltimore$8K
- Tara MorrisBaltimore$7K
- Simone BeattieBaltimore$7K
- Cairo KeenanBaltimore$4K
- Rakhmin KhoshayevBaltimore$4K
- Olga Duclos-LasnierBaltimore$4K
- Rashel CastelgrandeBaltimore$3K
- Samantha HammockBaltimore$2K
- Nam PhamBaltimore$2K
- Lindsey ManosBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.